FIELD: biotechnology.
SUBSTANCE: test system of M. smegmatis aphVIII + is designed to test various chemical compounds for their ability to inhibit specifically serine-threonine protein kinases M. smegmatis and represents a genetic structure shown in Fig. 4, constructed based on a modified shuttle vector pMIND with a deleted gene of resistance to kanamycin (pMINDKm-), including a gene of aminoglycoside phosphotransferase aphVIII from strain of Streptomyces rimosus ATCC 10970, cloned on sites of endonuclease restriction BamHI and SpeI, and implemented by the method of transformation into a strain of M. smegmatis mc2 155.
EFFECT: invention enables to expand the range of test systems.
4 dwg, 2 tbl, 3 ex
| Title | Year | Author | Number |
|---|---|---|---|
| TEST SYSTEM FOR HUMAN PROTEIN KINASE GSK3β INHIBITOR SCREENING | 2012 |
|
RU2528059C2 |
| QUATERNARY AMMONIUM DERIVATIVES OF 2-AMINOTHIOPHEN-3-CARBOXYLATES HAVING ANTI-TUBERCULOSIS ACTIVITY | 2016 |
|
RU2629369C1 |
| SUBSTITUTED AZOLO[1,2,4,5]TETRAZINES - INHIBITORS OF ANTIBACTERIAL SERINE-THREONINE PROTEIN KINASES | 2011 |
|
RU2462466C1 |
| RECOMBINANT PLASMID DNA pMind-vapB, CONTAINING vapB MSMEG_1283 GENE CODING NUCLEOTIDE SEQUENCE | 2012 |
|
RU2524148C2 |
| RECOMBINANT PLASMID DNA pMind-vapC, CONTAINING vapC MSMEG_1284 GENE CODING NUCLEOTIDE SEQUENCE | 2012 |
|
RU2524143C2 |
| ANTITUBERCULOUS THERAPEUTIC AGENT: COMPOSITION OF IMIDAZO[1,2-b]TETRAZINE AND PYRAZINAMIDE | 2013 |
|
RU2545458C2 |
| NEW EFFECTIVE THERAPEUTIC TARGET FOR TREATING TUBERCULOSIS | 2008 |
|
RU2474621C2 |
| USE OF ALLELIC VERSIONS OF PKS15 AND PE_PGRS54 GENES AS A MARKER OF INCREASED VIRULENCE OF MYCOBACTERIUM TUBERCULOSIS IN RELATION TO PEOPLE WITH LOW IMMUNITY | 2019 |
|
RU2737622C1 |
| AMINOTHIAZOLE DERIVATIVES OF USNIC ACID AS NOVEL ANTI-TUBERCULOSIS AGENTS | 2012 |
|
RU2483722C1 |
| RECOMBINANT PLASMID, Escherichia coli STRAIN, CHIMERIC PROTEIN AND THEIR APPLICATION | 2010 |
|
RU2422524C1 |
